Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Administered as a `5 Days On-2 Days Off' Oral Treatment in Glioblastoma Multiforme
Latest Information Update: 20 Jul 2015
At a glance
- Drugs Rubitecan (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 24 Sep 2005 New trial record.